Syros Pharmaceuticals Inc (SYRS)

$1.96

+0.02

(+1.03%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $1.95
    $2.00
    $1.96
    downward going graph

    0.51%

    Downside

    Day's Volatility :2.5%

    Upside

    2.0%

    downward going graph
  • $1.43
    $8.17
    $1.96
    downward going graph

    27.04%

    Downside

    52 Weeks Volatility :82.5%

    Upside

    76.01%

    downward going graph

Returns

PeriodSyros Pharmaceuticals IncRussel 2000Index (Russel 2000)
3 Months
-62.55%
0.0%
0.0%
6 Months
-56.89%
0.0%
0.0%
1 Year
-36.18%
0.0%
0.0%
3 Years
-95.58%
-20.1%
-20.1%

Highlights

Market Capitalization
51.7M
Book Value
- $0.24
Earnings Per Share (EPS)
-4.35
PEG Ratio
0.0
Wall Street Target Price
11.0
Profit Margin
0.0%
Operating Margin TTM
-2835.0%
Return On Assets TTM
-51.11%
Return On Equity TTM
-393.39%
Revenue TTM
4.1M
Revenue Per Share TTM
0.12
Quarterly Revenue Growth YOY
-3.3000000000000003%
Gross Profit TTM
14.9M
EBITDA
-116.0M
Diluted Eps TTM
-4.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.16
EPS Estimate Next Year
-2.8
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.77

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Syros Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 461.22%

Current $1.96
Target $11.00

Technicals Summary

Sell

Neutral

Buy

Syros Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Syros Pharmaceuticals Inc
Syros Pharmaceuticals Inc
28.05%
-56.89%
-36.18%
-95.58%
-97.79%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.33%
8.11%
21.28%
85.63%
257.49%
Novo Nordisk A/s
Novo Nordisk A/s
-12.25%
-9.71%
24.92%
138.38%
343.21%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
9.22%
72.73%
52.35%
34.04%
250.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.09%
12.2%
25.77%
150.7%
163.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Syros Pharmaceuticals Inc
Syros Pharmaceuticals Inc
6.88
NA
0.0
-2.16
-3.93
-0.51
NA
-0.24
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Syros Pharmaceuticals Inc
Syros Pharmaceuticals Inc
Buy
$51.7M
-97.79%
6.88
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
257.49%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
343.21%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
250.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.62%
32.84
-4.74%

Insights on Syros Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.76M → 386.0K (in $), with an average decrease of 89.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -3.70M → -23.32M (in $), with an average decrease of 529.1% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.3% return, outperforming this stock by 88.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.0% return, outperforming this stock by 129.6%

Institutional Holdings

  • Bain Capital Life Sciences Investors, LLC

    10.26%

  • Artal Group S A

    9.34%

  • Adage Capital Partners Gp LLC

    7.73%

  • Samsara BioCapital, LLC

    6.66%

  • Avidity Partners Management LP

    6.24%

  • Point72 Asset Management, L.P.

    5.49%

Company Information

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Organization
Syros Pharmaceuticals Inc
Employees
68
CEO
Mr. Conley Chee
Industry
Health Technology

Discover More

FAQs